Patient characteristics
| Characteristic . | IHC . | ELISA . | mRNA . |
|---|---|---|---|
| n | 84 | 41 | 261 |
| Median age, y (range) | 58 (19-82) | 61 (24-81) | < 35 y, n = 76 35-60 y, n = 177 ≥ 60 y, n =3217 |
| Sex, % | |||
| Male | 55 | 49 | * |
| Female | 45 | 51 | * |
| FAB classification (unclassified), % | 0 | 0 | 3.8 |
| M0 | 1.4 | 0 | 2.1 |
| M1 | 11.3 | 23.1 | 22.1 |
| M2 | 29.6 | 28.2 | 23.2 |
| M3 | 4.2 | 2.6 | 6.7 |
| M4 | 21.1 | 17.9 | 18.6 |
| M5 | 22.5 | 25.6 | 22.5 |
| M6 | 8.5 | 2.6 | 1 |
| M7 | 1.4 | 0 | 0 |
| Karyotype, % | |||
| Favorable: 8/21; 15/17 | 9.5 | 19.5 | 20 |
| Intermediate: normal, +8, +22, other | 37.8 | 46.3 | 47 |
| Unfavorable: complex, −5, −7, 11q | 20.3 | 9.8 | 15.1 |
| Unknown | 32.4 | 24.4 | 17.9 |
| CR following therapy, % | 64 | 69 | * |
| Median follow-up, mo (range) | 28 (1-103) | 15 (1-70) | 43 (1-213) |
| Characteristic . | IHC . | ELISA . | mRNA . |
|---|---|---|---|
| n | 84 | 41 | 261 |
| Median age, y (range) | 58 (19-82) | 61 (24-81) | < 35 y, n = 76 35-60 y, n = 177 ≥ 60 y, n =3217 |
| Sex, % | |||
| Male | 55 | 49 | * |
| Female | 45 | 51 | * |
| FAB classification (unclassified), % | 0 | 0 | 3.8 |
| M0 | 1.4 | 0 | 2.1 |
| M1 | 11.3 | 23.1 | 22.1 |
| M2 | 29.6 | 28.2 | 23.2 |
| M3 | 4.2 | 2.6 | 6.7 |
| M4 | 21.1 | 17.9 | 18.6 |
| M5 | 22.5 | 25.6 | 22.5 |
| M6 | 8.5 | 2.6 | 1 |
| M7 | 1.4 | 0 | 0 |
| Karyotype, % | |||
| Favorable: 8/21; 15/17 | 9.5 | 19.5 | 20 |
| Intermediate: normal, +8, +22, other | 37.8 | 46.3 | 47 |
| Unfavorable: complex, −5, −7, 11q | 20.3 | 9.8 | 15.1 |
| Unknown | 32.4 | 24.4 | 17.9 |
| CR following therapy, % | 64 | 69 | * |
| Median follow-up, mo (range) | 28 (1-103) | 15 (1-70) | 43 (1-213) |
Not known.